Kristina Brooks
Concepts (289)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 30 | 2026 | 914 | 6.050 |
Why?
| | HIV Infections | 36 | 2026 | 3215 | 4.620 |
Why?
| | Adenine | 13 | 2026 | 339 | 3.130 |
Why?
| | Pregnancy Complications, Infectious | 12 | 2026 | 438 | 2.820 |
Why?
| | Tenofovir | 16 | 2026 | 300 | 2.770 |
Why?
| | Alanine | 12 | 2026 | 171 | 2.600 |
Why?
| | Antiviral Agents | 9 | 2026 | 779 | 2.240 |
Why?
| | Emtricitabine | 12 | 2026 | 209 | 1.870 |
Why?
| | Adenosine Monophosphate | 3 | 2026 | 87 | 1.750 |
Why?
| | Isoniazid | 3 | 2026 | 71 | 1.640 |
Why?
| | Pre-Exposure Prophylaxis | 8 | 2026 | 272 | 1.620 |
Why?
| | Tandem Mass Spectrometry | 6 | 2026 | 576 | 1.570 |
Why?
| | Dried Blood Spot Testing | 6 | 2026 | 129 | 1.540 |
Why?
| | Polyphosphates | 5 | 2026 | 46 | 1.360 |
Why?
| | Sofosbuvir | 5 | 2026 | 63 | 1.350 |
Why?
| | Leukocytes, Mononuclear | 6 | 2026 | 585 | 1.240 |
Why?
| | Antitubercular Agents | 3 | 2026 | 212 | 1.210 |
Why?
| | Heterocyclic Compounds, 3-Ring | 6 | 2026 | 44 | 1.190 |
Why?
| | Phosphorous Acids | 2 | 2019 | 15 | 1.180 |
Why?
| | Organophosphates | 7 | 2026 | 179 | 1.170 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 4 | 2026 | 25 | 0.900 |
Why?
| | Rifampin | 4 | 2026 | 80 | 0.830 |
Why?
| | Darunavir | 1 | 2023 | 20 | 0.800 |
Why?
| | Benzimidazoles | 4 | 2026 | 191 | 0.790 |
Why?
| | Pharmacology, Clinical | 1 | 2023 | 9 | 0.780 |
Why?
| | Hepatitis C | 2 | 2026 | 251 | 0.780 |
Why?
| | Pregnancy | 20 | 2026 | 7230 | 0.760 |
Why?
| | Fluorenes | 2 | 2020 | 46 | 0.740 |
Why?
| | Medication Adherence | 7 | 2026 | 535 | 0.740 |
Why?
| | Postpartum Period | 9 | 2026 | 377 | 0.740 |
Why?
| | Drug Monitoring | 4 | 2024 | 399 | 0.730 |
Why?
| | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 2 | 2018 | 19 | 0.690 |
Why?
| | Blood Platelets | 1 | 2025 | 382 | 0.680 |
Why?
| | Dideoxynucleosides | 3 | 2026 | 27 | 0.660 |
Why?
| | Cobicistat | 4 | 2023 | 5 | 0.630 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 790 | 0.620 |
Why?
| | Chromatography, Liquid | 5 | 2026 | 453 | 0.600 |
Why?
| | Neutrophils | 1 | 2025 | 1133 | 0.580 |
Why?
| | Biomarkers, Pharmacological | 1 | 2018 | 26 | 0.560 |
Why?
| | Drug Interactions | 6 | 2019 | 405 | 0.550 |
Why?
| | Antibiotics, Antitubercular | 1 | 2018 | 35 | 0.550 |
Why?
| | Humans | 62 | 2026 | 146342 | 0.550 |
Why?
| | HIV Integrase Inhibitors | 1 | 2019 | 80 | 0.530 |
Why?
| | Busulfan | 1 | 2017 | 15 | 0.530 |
Why?
| | Hepatitis C, Chronic | 3 | 2026 | 150 | 0.530 |
Why?
| | Female | 43 | 2026 | 79499 | 0.530 |
Why?
| | Transplantation Conditioning | 1 | 2017 | 193 | 0.480 |
Why?
| | Adult | 28 | 2026 | 41087 | 0.470 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 68 | 0.470 |
Why?
| | Desiccation | 1 | 2015 | 26 | 0.450 |
Why?
| | Complementary Therapies | 1 | 2016 | 93 | 0.450 |
Why?
| | Genotyping Techniques | 1 | 2015 | 74 | 0.450 |
Why?
| | Carbamates | 2 | 2026 | 52 | 0.450 |
Why?
| | Blood | 1 | 2015 | 107 | 0.440 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2026 | 47 | 0.430 |
Why?
| | Infectious Disease Transmission, Vertical | 4 | 2025 | 188 | 0.430 |
Why?
| | Models, Biological | 5 | 2026 | 1761 | 0.410 |
Why?
| | Lamivudine | 2 | 2025 | 63 | 0.410 |
Why?
| | Microbial Sensitivity Tests | 1 | 2015 | 367 | 0.410 |
Why?
| | Specimen Handling | 1 | 2015 | 178 | 0.400 |
Why?
| | Bronchitis | 1 | 2013 | 28 | 0.380 |
Why?
| | Prospective Studies | 9 | 2025 | 8123 | 0.380 |
Why?
| | Young Adult | 17 | 2026 | 14330 | 0.380 |
Why?
| | Pyridones | 5 | 2026 | 210 | 0.380 |
Why?
| | Rare Diseases | 1 | 2013 | 117 | 0.360 |
Why?
| | Piperazines | 5 | 2026 | 368 | 0.360 |
Why?
| | Cross-Over Studies | 4 | 2023 | 615 | 0.350 |
Why?
| | Reproducibility of Results | 3 | 2026 | 3416 | 0.350 |
Why?
| | Drug Combinations | 5 | 2025 | 400 | 0.350 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2017 | 704 | 0.340 |
Why?
| | Cytokines | 2 | 2018 | 2081 | 0.330 |
Why?
| | Protease Inhibitors | 2 | 2022 | 103 | 0.330 |
Why?
| | HIV-1 | 2 | 2025 | 913 | 0.330 |
Why?
| | Oxazines | 3 | 2025 | 36 | 0.320 |
Why?
| | Fontan Procedure | 1 | 2013 | 200 | 0.320 |
Why?
| | Viral Load | 4 | 2026 | 526 | 0.310 |
Why?
| | Male | 24 | 2026 | 73396 | 0.290 |
Why?
| | Blood Chemical Analysis | 2 | 2019 | 109 | 0.280 |
Why?
| | Transgender Persons | 2 | 2022 | 213 | 0.280 |
Why?
| | Glycerophospholipids | 2 | 2025 | 39 | 0.270 |
Why?
| | Benzamides | 2 | 2026 | 226 | 0.270 |
Why?
| | Janus Kinase 1 | 2 | 2018 | 26 | 0.270 |
Why?
| | Janus Kinase 2 | 2 | 2018 | 31 | 0.270 |
Why?
| | Azetidines | 2 | 2018 | 45 | 0.270 |
Why?
| | Janus Kinase Inhibitors | 2 | 2018 | 27 | 0.260 |
Why?
| | Hepacivirus | 3 | 2026 | 237 | 0.260 |
Why?
| | Dabigatran | 2 | 2017 | 30 | 0.250 |
Why?
| | Healthy Volunteers | 5 | 2018 | 218 | 0.250 |
Why?
| | Tablets | 2 | 2025 | 41 | 0.250 |
Why?
| | Lactation | 3 | 2023 | 193 | 0.240 |
Why?
| | Phthalimides | 1 | 2026 | 3 | 0.240 |
Why?
| | Solid Phase Extraction | 1 | 2026 | 28 | 0.240 |
Why?
| | Hydrazines | 1 | 2026 | 37 | 0.240 |
Why?
| | Limit of Detection | 1 | 2026 | 92 | 0.240 |
Why?
| | Clofazimine | 1 | 2026 | 15 | 0.230 |
Why?
| | Injections | 1 | 2026 | 201 | 0.230 |
Why?
| | Delayed-Action Preparations | 1 | 2026 | 192 | 0.220 |
Why?
| | Pregnancy Trimester, Third | 2 | 2025 | 117 | 0.220 |
Why?
| | Levofloxacin | 1 | 2025 | 21 | 0.220 |
Why?
| | Administration, Oral | 6 | 2026 | 872 | 0.220 |
Why?
| | Infant | 7 | 2025 | 10114 | 0.220 |
Why?
| | Middle Aged | 11 | 2026 | 36619 | 0.210 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2026 | 588 | 0.210 |
Why?
| | Milk, Human | 1 | 2026 | 176 | 0.200 |
Why?
| | Linear Models | 1 | 2026 | 857 | 0.200 |
Why?
| | Sulfonamides | 2 | 2018 | 594 | 0.200 |
Why?
| | Macaca nemestrina | 1 | 2023 | 29 | 0.200 |
Why?
| | Prenatal Care | 1 | 2024 | 310 | 0.180 |
Why?
| | Neonatal Sepsis | 1 | 2022 | 9 | 0.180 |
Why?
| | Breast Feeding | 2 | 2023 | 447 | 0.180 |
Why?
| | Practice Guidelines as Topic | 2 | 2023 | 1591 | 0.170 |
Why?
| | Cell Phone | 1 | 2022 | 83 | 0.170 |
Why?
| | HIV | 1 | 2023 | 249 | 0.170 |
Why?
| | Adolescent | 9 | 2022 | 22557 | 0.170 |
Why?
| | Osteoporotic Fractures | 1 | 2022 | 62 | 0.170 |
Why?
| | Hip Fractures | 1 | 2022 | 88 | 0.160 |
Why?
| | Ritonavir | 2 | 2020 | 76 | 0.160 |
Why?
| | Pregnancy Outcome | 2 | 2024 | 503 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 2 | 2017 | 122 | 0.160 |
Why?
| | Mobile Applications | 1 | 2022 | 196 | 0.150 |
Why?
| | Antithrombins | 2 | 2017 | 71 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2022 | 429 | 0.150 |
Why?
| | Osteoporosis | 1 | 2022 | 240 | 0.140 |
Why?
| | Fetus | 1 | 2023 | 800 | 0.140 |
Why?
| | Alcohol Drinking | 1 | 2025 | 850 | 0.140 |
Why?
| | Hereditary Autoinflammatory Diseases | 1 | 2018 | 13 | 0.140 |
Why?
| | Ethanol | 1 | 2023 | 630 | 0.140 |
Why?
| | COP9 Signalosome Complex | 1 | 2017 | 5 | 0.130 |
Why?
| | Drug Dosage Calculations | 1 | 2017 | 27 | 0.130 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2017 | 12 | 0.130 |
Why?
| | Treatment Outcome | 6 | 2026 | 11821 | 0.130 |
Why?
| | Jejunostomy | 1 | 2017 | 13 | 0.130 |
Why?
| | Hair Cells, Auditory, Inner | 1 | 2017 | 17 | 0.130 |
Why?
| | Morpholinos | 1 | 2017 | 30 | 0.130 |
Why?
| | Latent Tuberculosis | 1 | 2018 | 71 | 0.130 |
Why?
| | Administration, Intravenous | 1 | 2017 | 172 | 0.120 |
Why?
| | Interferons | 1 | 2018 | 186 | 0.120 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2016 | 18 | 0.120 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 416 | 0.120 |
Why?
| | Inflammation | 2 | 2018 | 2919 | 0.120 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2016 | 6 | 0.120 |
Why?
| | Benzopyrans | 2 | 2026 | 31 | 0.110 |
Why?
| | Equipment and Supplies | 1 | 2015 | 36 | 0.110 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2016 | 163 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1763 | 0.110 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 52 | 0.110 |
Why?
| | Gadolinium | 1 | 2016 | 78 | 0.110 |
Why?
| | Receptors, LDL | 1 | 2015 | 53 | 0.110 |
Why?
| | Enteral Nutrition | 1 | 2017 | 212 | 0.110 |
Why?
| | Radiopharmaceuticals | 1 | 2016 | 210 | 0.110 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2016 | 141 | 0.110 |
Why?
| | Blood Coagulation | 1 | 2016 | 267 | 0.110 |
Why?
| | Amides | 2 | 2026 | 100 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1036 | 0.100 |
Why?
| | Child | 7 | 2025 | 22693 | 0.100 |
Why?
| | Autoimmune Diseases | 1 | 2017 | 467 | 0.100 |
Why?
| | Doxorubicin | 1 | 2016 | 416 | 0.100 |
Why?
| | Tissue Plasminogen Activator | 1 | 2015 | 245 | 0.100 |
Why?
| | Telemedicine | 1 | 2022 | 966 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 315 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2113 | 0.090 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2022 | 89 | 0.090 |
Why?
| | Intestinal Mucosa | 1 | 2017 | 666 | 0.090 |
Why?
| | Pyrimidines | 2 | 2026 | 532 | 0.090 |
Why?
| | Benchmarking | 2 | 2024 | 193 | 0.080 |
Why?
| | Blood Preservation | 1 | 2015 | 346 | 0.080 |
Why?
| | Infant, Newborn | 4 | 2025 | 6460 | 0.080 |
Why?
| | Influenza, Human | 1 | 2017 | 640 | 0.080 |
Why?
| | Aged | 4 | 2022 | 26432 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 604 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1408 | 0.070 |
Why?
| | Contrast Media | 3 | 2016 | 493 | 0.070 |
Why?
| | Compassionate Use Trials | 2 | 2018 | 7 | 0.070 |
Why?
| | Biomarkers | 3 | 2025 | 4340 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2026 | 2070 | 0.060 |
Why?
| | Thrombin Time | 2 | 2017 | 13 | 0.060 |
Why?
| | Purines | 2 | 2018 | 188 | 0.060 |
Why?
| | Furans | 1 | 2026 | 26 | 0.060 |
Why?
| | Dideoxyadenosine | 1 | 2025 | 4 | 0.060 |
Why?
| | Monte Carlo Method | 1 | 2026 | 151 | 0.060 |
Why?
| | Drug Resistance, Viral | 1 | 2026 | 127 | 0.060 |
Why?
| | Cyclopropanes | 1 | 2025 | 83 | 0.050 |
Why?
| | Viremia | 1 | 2026 | 158 | 0.050 |
Why?
| | Holistic Health | 1 | 2024 | 12 | 0.050 |
Why?
| | South Africa | 1 | 2026 | 262 | 0.050 |
Why?
| | Pyrazoles | 2 | 2018 | 517 | 0.050 |
Why?
| | Brain | 1 | 2016 | 2991 | 0.050 |
Why?
| | Animals | 4 | 2023 | 38106 | 0.050 |
Why?
| | Cost-Benefit Analysis | 3 | 2022 | 640 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2022 | 3647 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2016 | 3926 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2015 | 8391 | 0.050 |
Why?
| | Fetal Blood | 1 | 2025 | 325 | 0.050 |
Why?
| | Anti-Retroviral Agents | 1 | 2024 | 250 | 0.050 |
Why?
| | Child, Preschool | 4 | 2025 | 11913 | 0.050 |
Why?
| | Ultrasonography | 2 | 1996 | 788 | 0.040 |
Why?
| | Diphosphates | 1 | 2021 | 20 | 0.040 |
Why?
| | Lung | 1 | 2015 | 4122 | 0.040 |
Why?
| | Cohort Studies | 2 | 2026 | 6077 | 0.040 |
Why?
| | Hormones | 1 | 2022 | 134 | 0.040 |
Why?
| | Genome, Fungal | 1 | 2002 | 48 | 0.040 |
Why?
| | United States | 2 | 2016 | 16136 | 0.040 |
Why?
| | Schizosaccharomyces | 1 | 2002 | 85 | 0.040 |
Why?
| | HTLV-I Infections | 1 | 2000 | 29 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2022 | 248 | 0.040 |
Why?
| | Dermatitis | 1 | 2000 | 20 | 0.040 |
Why?
| | Drug Approval | 1 | 2020 | 94 | 0.040 |
Why?
| | Lopinavir | 1 | 2020 | 30 | 0.040 |
Why?
| | Simethicone | 2 | 1996 | 5 | 0.040 |
Why?
| | Cellulose | 2 | 1996 | 55 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 31 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 517 | 0.030 |
Why?
| | Capsules | 1 | 2018 | 40 | 0.030 |
Why?
| | Testosterone | 1 | 2022 | 419 | 0.030 |
Why?
| | Developing Countries | 1 | 2020 | 312 | 0.030 |
Why?
| | Nanomedicine | 1 | 2018 | 47 | 0.030 |
Why?
| | Acoustic Maculae | 1 | 2017 | 1 | 0.030 |
Why?
| | Oocysts | 1 | 2017 | 7 | 0.030 |
Why?
| | Drug Compounding | 1 | 2018 | 106 | 0.030 |
Why?
| | Viral Matrix Proteins | 1 | 2017 | 28 | 0.030 |
Why?
| | Saccule and Utricle | 1 | 2017 | 13 | 0.030 |
Why?
| | Placebos | 1 | 2017 | 192 | 0.030 |
Why?
| | Proteinuria | 1 | 2017 | 103 | 0.030 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 112 | 0.030 |
Why?
| | Embryo, Nonmammalian | 1 | 2017 | 171 | 0.030 |
Why?
| | Area Under Curve | 1 | 2017 | 335 | 0.030 |
Why?
| | Influenza A virus | 1 | 2017 | 120 | 0.030 |
Why?
| | Headache | 1 | 2017 | 150 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 432 | 0.030 |
Why?
| | Tubulin | 1 | 2017 | 124 | 0.030 |
Why?
| | Patient Selection | 1 | 2020 | 728 | 0.030 |
Why?
| | Hand-Foot Syndrome | 1 | 2016 | 2 | 0.030 |
Why?
| | Axons | 1 | 2017 | 205 | 0.030 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 12 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 104 | 0.030 |
Why?
| | Carboplatin | 1 | 2016 | 168 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1064 | 0.030 |
Why?
| | Injections, Spinal | 1 | 2015 | 120 | 0.030 |
Why?
| | Actins | 1 | 2017 | 422 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2016 | 147 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2015 | 173 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2126 | 0.030 |
Why?
| | Intestines | 1 | 2017 | 351 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 449 | 0.030 |
Why?
| | Epithelium | 1 | 2015 | 295 | 0.030 |
Why?
| | Endocytosis | 1 | 2015 | 170 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2020 | 609 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 745 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 1996 | 220 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2015 | 1041 | 0.020 |
Why?
| | Body Weight | 1 | 2017 | 968 | 0.020 |
Why?
| | Quality Improvement | 1 | 2022 | 1354 | 0.020 |
Why?
| | Zebrafish | 1 | 2017 | 536 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 642 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1849 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 731 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 1996 | 478 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 650 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2936 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3347 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2488 | 0.020 |
Why?
| | Phenotype | 1 | 2016 | 3206 | 0.020 |
Why?
| | Liver | 1 | 2015 | 1864 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 2786 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 6034 | 0.010 |
Why?
| | Gene Duplication | 1 | 2002 | 67 | 0.010 |
Why?
| | Chromosomes, Fungal | 1 | 2002 | 43 | 0.010 |
Why?
| | Eukaryotic Cells | 1 | 2002 | 39 | 0.010 |
Why?
| | DNA, Fungal | 1 | 2002 | 76 | 0.010 |
Why?
| | Genetic Diseases, Inborn | 1 | 2002 | 45 | 0.010 |
Why?
| | Centromere | 1 | 2002 | 62 | 0.010 |
Why?
| | Fungal Proteins | 1 | 2002 | 137 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17438 | 0.010 |
Why?
| | Sensitivity and Specificity | 2 | 1996 | 1998 | 0.010 |
Why?
| | Introns | 1 | 2002 | 257 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2002 | 508 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 2000 | 23 | 0.010 |
Why?
| | Immunoglobulins | 1 | 2000 | 162 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2002 | 834 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 771 | 0.010 |
Why?
| | HLA Antigens | 1 | 2000 | 241 | 0.010 |
Why?
| | Base Sequence | 1 | 2002 | 2123 | 0.010 |
Why?
| | Haplotypes | 1 | 2000 | 506 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2000 | 416 | 0.010 |
Why?
| | Mice | 1 | 2015 | 18297 | 0.010 |
Why?
| | Artifacts | 1 | 1996 | 143 | 0.010 |
Why?
| | Abdomen | 1 | 1996 | 142 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2022 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2000 | 5439 | 0.000 |
Why?
|
|
Brooks's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|